Neuroscientist in Dementia / Banner Health 🇺🇸/ University of Gothenburg 🇸🇪
Scottsdale, AZ
- Tweets 3,342
- Following 771
- Followers 2,164
- Likes 1,221
Nicholas Ashton retweeted
In this Global CTE Summit session on progress toward diagnosing CTE during life, Dr. @NicholasAshton shares findings from Banner Research's Fluid Biomarker Program.
Dr. Ashton & colleagues are exploring how techniques used to detect Alzheimer's may be applicable for CTE.
1
3
9
580
Nicholas Ashton retweeted
This multi-center study demonstrates that dried and capillary blood as a minimally invasive, scalable approach for #Alzheimers #biomarker testing in research, with potential for widely scalable population-based research, especially in resource-limited settings. @NicholasAshton @wagnersbrum
nature.com/articles/s41591-0…
8
23
8,015
Nicholas Ashton retweeted
New @Nature
Detection of Alzheimer's pathology from a dried blood spot derived from capillaries with capability of quantifying p-tau217 and other neuromarker levels
nature.com/articles/s41591-0…
4
56
218
27,261
Nicholas Ashton retweeted
The p-tau217 biomarker by age and prevalence of Alzheimer's disease in the community of ~12,000 people in Norway
nature.com/articles/s41586-0…
4
45
182
30,825
Nicholas Ashton retweeted
'The study also found that people with lower education levels have higher p-Tau217 levels.
“That finding kind of took my breath away”
nature.com/articles/d41586-0…
4
44
151
64,950
Nicholas Ashton retweeted
Hot off the press!
P-Tau 217 has been measured in over 11,000 participants and prevalence of #AlzheimersDisease pathology has been characterised
nature.com/articles/s41586-0…
@AarslandDag @NicholasAshton @KingsIoPPN @Nature
6
18
1,857
Nicholas Ashton retweeted
p-tau217, the breakthrough blood test, prediction of amyloid-β burden and Alzheimer's disease in people with no symptoms, no cognitive impairment
jamanetwork.com/journals/jam…
18
130
573
48,281
Nicholas Ashton retweeted
Really excited to our announce the publication of our meta-analysis of p-tau217 differences in amyloid pos/neg cognitively unimpaired individuals. Very honored to have co-authored this with @NicholasAshton! pubmed.ncbi.nlm.nih.gov/4132…
1
3
174
Our new meta-analysis for plasma p-tau217 for detecting preclinical Alzheimer’s pathology in cogntively unimpaired older adults
🩸🧠🧪📈
pubmed.ncbi.nlm.nih.gov/4132…
1
9
579
We tested 6 p-tau217 assays to see if serum can replace plasma.
✔️ Lumipulse showed near-perfect correlation (ρ=0.98)
⚠️ Serum needs its own cutoffs
Bottom line: Serum p-tau217 is ready for wider clinical + research use—with proper validation
pubmed.ncbi.nlm.nih.gov/4123…
1
3
207
Diagnosing Alzheimer’s in adults with Down syndrome is tough—but crucial. In 2329 participants, plasma #pTau217 had high accuracy for AD pathology in this high-risk population.
#AlzheimersDisease #DownSyndrome #Biomarkers #pTau217 #Neurodegeneration
pubmed.ncbi.nlm.nih.gov/4121…
2
6
411
Nicholas Ashton retweeted
Why does this matter?
Knowing when biomarkers change helps us stage disease and optimize timing for treatments—crucial for trials & patients. (6/6)
🙏 Thanks to all collaborators!
@NicholasAshton @SebastianPalmqv @OskarHansson9 @biofinder_study
1
2
188
Nicholas Ashton retweeted
Learn about #brainhealth and navigate advances in #AlzheimersDisease with this two-part workshop series at #GSA2025. Join us on 11/13 at 11:30 AM EST & 11/14 at 6:00 AM EST bit.ly/Boston25-T #Gerontology @_BrightFocus @NicholasAshton @mboustan @BarakGaster @ScottKaiserMD
3
7
306
Nicholas Ashton retweeted
🚨Just published in @NatureNeuro🚨
Led by @jpfsouza33, this study used imaging & fluid biomarkers to reveal that microglia modulate Aβ-related astrocyte reactivity, which in turn contributes to Alzheimer’s disease progression.
🔗 nature.com/articles/s41593-0…
2
9
19
1,818
Exciting to see cerebral amyloid angiopathy (CAA) gaining attention in @alzforum #AAIC25 roundup, particularly highlighting Alpana Singh's work using NULISA @AlamarBio technology.
@BannerAlzheimer
lnkd.in/dcSGwyyg
2
403
Yesterday, we joined >600 dementia researchers, clinicians & students at the #Arizona #Alzheimer consortium (AAC) annual conference
We presented our latest work on fully-automated blood biomarker tests for #AD & discovery proteomics for non-AD pathologies. @BannerAlzheimer
2
399
Excited to invite you to our featured research session on remote biomarker collection in Alzheimer's disease— TODAY (Monday) 2 PM in Hall F #AAIC25!
We’ll highlight diverse blood sampling methods, app-based cognitive and speech monitoring.
1
1
14
635
I’m delighted & tremendously proud to attend my first #AAIC as a principal investigator alongside my incredible team.
We invite you to attend our oral presentations, sessions, and poster discussions—please stop by and engage with our work! hashtag #AAIC2025 @alzassociation
3
2
29
1,221
Nicholas Ashton retweeted
"Clocks" that relate amyloid and tau PET to time were used to examine the timing of biomarker changes (including plasma biomarkers) in Alzheimer disease. Plasma Aβ42/40 changes very early! onlinelibrary.wiley.com/doi/…
#ENDALZ @FNIH_Org
9
36
2,561
Nicholas Ashton retweeted
🚨 In this paper in @NatureCommuniations, we find that Down syndrome #Alzheimer exhibits unique pathological features compared with sporadic late-onset and autosomal dominant AD with important implications for treatment strategies.
nature.com/articles/s41467-0…
2
8
30
1,948